Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Would Cough Up As Much As $31bn More For Rx-Only DXM Over 10 Years

Executive Summary

A study the Consumer Healthcare Products Association commissioned finds OTC access to the cough suppressant dextromethorphan will save consumers between $22bn and $31bn through 2025 compared to a scenario of the product moving to Rx-only.


Related Content

Consumer Health Care Roundup: DXM Abuse Rate Stays Steady; OTC Device Claim Fails
OTC Drug Industry Could Stand To Gain With 'Pragmatist' In White House
CBO Overestimates Costs Of Enforcing DXM Sales Age-Restriction – CHPA
Education To Prevent Abuse Reinforces DMX Safety As OTC – CHPA Study
Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction
DXM Sales Age Restriction Reaches Florida; CHPA Navigates PSE Road
Developing Antitussive Alternatives To DXM Would Offset Commercial Risk
FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts